Altman Peter 4

What Happened
Peter Altman, President, CEO and a director of BioCardia, purchased 5,400 shares of BCDA in an open-market/private purchase on July 8, 2026. The filing reports a weighted-average price of $0.96 per share for a reported total of $5,208. This was a purchase (code P), which is generally viewed as a direct insider buy rather than a sale.

Key Details

• Transaction date: 2026-07-08 (reported same day; filing appears timely)
• Reported price: weighted average $0.96 per share (range of individual trades $0.92–$1.05 per F1)
• Shares acquired: 5,400; reported total value: $5,208
• Shares owned after transaction: Not disclosed in the filing
• Footnote: F1 states the purchase was executed in multiple trades at prices between $0.92 and $1.05; the weighted average is reported and the reporting person will provide per-trade details to the SEC or issuer upon request

Context
Insider purchases can signal confidence but do not by themselves prove future stock performance. This is a small-dollar open-market purchase by the CEO; for more detail on the per-trade prices or post-transaction holdings, investors can request the supplemental information referenced in the filing.